ALBI Grade (Liver)ASTCT Grading ATA Thyroid Risk BCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPI CML ELTS Score CNS-IPI CTCAE v5.0 Calvert Formula DIPSS-Plus (Myelofibrosis)Deauville Score EAU NMIBC Risk ECOG Performance Status ELN 2022 Risk (AML)ELN CML Milestones FIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2 Fleischner 2017 Guidelines Fong Clinical Risk Score HCT-CI (Sorror Score)HPV/p16 Oropharynx IGCCCG Risk (Testicular)IMDC (Heng) Criteria IMWG Myeloma Frailty IPSS-M (Molecular MDS)ISUP Grade Groups Karnofsky Status (KPS)Khorana Score Lugano Classification Lung-RADS v2022 MIPI-b (Biological)MRD Assessment Framework MSI/MMR Interpretation Mayo 20/2/20 (SMM)NCCN Prostate Risk NCCN-IPI (DLBCL)NSCLC GPA Oncotype DX Recurrence Opioid Equianalgesic PD-L1 TPS Interpretation PERCIST 2.0 PREDICT v3.0 Platinum-Free Interval R2-ISS (Revised 2)RANO 2.0 RCB (Residual Cancer Burden)RECIST 1.1 ROMA Score SAVER Score SINS Score SLiM-CRAB Criteria Sedlis/Peters Criteria TNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AML Z0011 Eligibility iRECIST iwCLL 2018 Response mRECIST (HCC)mRENAL Score mrTRG (Rectal MRI)

Recent Journal Updates

Intensive Care MedicineJun 8, 2026

Is acute respiratory distress syndrome a preventable disease?

Clinical Context

We think this has broad domain relevance to mRECIST for HCC.

DiabetologiaJun 8, 2026

Genetics of MASLD: a diabetes perspective

Clinical Context

We think this has broad domain relevance to mRECIST for HCC.

Intensive Care MedicineJun 8, 2026

Patient blood management in general intensive care patients

Clinical Context

We think this has broad domain relevance to mRECIST for HCC.

mRECIST (HCC)

MRECIST HCCModified Response Evaluation for Liver Cancer

Viable Tumor Assessment

Assign Response Category

HCC Clinical pearl

Unlike conventional RECIST, mRECIST measures only the enhancing (viable) portion of the tumor. This is crucial for local therapies like TACE or ablation where the tumor mass may remain but the cancer cells are necrotic.

Response Outlook

SD

Clinical Strategy

Stable Disease. No significant change in viable (enhancing) tumor burden.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Routinely used to assess response in HCC patients undergoing locoregional therapies (TACE, RFA, Y90 Radioembolization).

Increasingly used in clinical trials evaluating systemic targeted therapies (TKIs like sorafenib/lenvatinib) and immunotherapies.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the BCLC 2022 Staging (HCC), ALBI Grade (Liver) or the RECIST 1.1 to formulate a comprehensive care plan.

Last Comprehensive Review: 2026